Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardiovascular Tests



    VANCOUVER, June 26 /CNW/ - Response Biomedical Corporation (TSX: RBM,
OTCBB: RPBIF) announced today that it has entered into an agreement granting
rights to Roche Diagnostics to market its line of cardiovascular point-of-care
(POC) tests worldwide. Roche Diagnostics' comprehensive sales and marketing
infrastructure allows for broad worldwide penetration of Response Biomedical's
cardiovascular line.
    "We are extremely pleased to partner with Roche Diagnostics, a world
leader in clinical diagnostics. Their distribution and marketing capabilities
will be strategically important in quickly expanding the reach of our products
into the marketplace," said S. Wayne Kay, Chief Executive Officer, Response
Biomedical Corporation. "This collaboration significantly enhances our
commercialization strategy and sets the stage for rapid market expansion.
Furthermore, we are exploring the application of our proprietary RAMP(R)
platform to other clinical areas where its unique advantages can be leveraged
to improve patient care."
    The RAMP(R) cardiovascular product line includes Troponin I, CK-MB,
Myoglobin and NT-proBNP Tests. The Company is awaiting U.S. Food and Drug
Administration 510(k) clearance before the NT-proBNP Test can be sold in the
U.S.
    "Our collaboration with Response Biomedical Corporation is an important
step to further expand our presence in the dynamically growing POC cardiac
market, expecting double-digit growth over the coming years," said Dirk H.
Ehlers, Head of Roche Professional Diagnostics. "The Roche POC portfolio will
be enhanced by the addition of the RAMP(R) cardiovascular product line and
will allow us to target key global markets by responding to customer demands
for choice in systems for different throughput and parameter needs."

    About Response Biomedical

    Response Biomedical develops, manufactures and markets rapid on-site
diagnostic tests for use with its RAMP(R) Platform for clinical and
environmental applications. RAMP(R) represents a new paradigm in diagnostics
that provides high sensitivity and reliable information in minutes. It is
ideally suited to both point-of-care testing and laboratory use. The RAMP(R)
system consists of a Reader and single-use disposable test cartridges, and has
the potential to be adapted to more than 250 medical and non-medical tests
currently performed in laboratories. RAMP(R) clinical tests are commercially
available for the early detection of heart attack and congestive heart
failure.
    In late 2006, the Company formed a strategic alliance with 3M Company to
commercialize rapid infectious disease tests. In the non-clinical market,
RAMP(R) Tests are currently provided for the environmental detection of West
Nile Virus, and Biodefense applications including the rapid on-site detection
of anthrax, smallpox, ricin and botulinum toxin. Several other product
applications are under development. Response has achieved CE Marking and its
Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.

    Response Biomedical is a publicly traded company, listed on the TSX under
the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol
"RPBIF". For further information, please visit the Company's website at
www.responsebio.com.

    About Roche

    Headquartered in Basel, Switzerland, Roche is one of the world's leading
research-focused healthcare groups in the fields of pharmaceuticals and
diagnostics. As the world's biggest biotech company and an innovator of
products and services for the early detection, prevention, diagnosis and
treatment of diseases, the Group contributes on a broad range of fronts to
improving people's health and quality of life. Roche is the world leader in
in-vitro diagnostics and drugs for cancer and transplantation, and is a market
leader in virology. It is also active in other major therapeutic areas such as
autoimmune diseases, inflammatory and metabolic disorders and diseases of the
central nervous system. In 2007 sales by the Pharmaceuticals Division totaled
36.8 billion Swiss francs, and the Diagnostics Division posted sales of
9.3 billion francs. Roche has R&D agreements and strategic alliances with
numerous partners, including majority ownership interests in Genentech and
Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide,
the Group employs about 79,000 people. Additional information is available on
the Internet at www.roche.com.

    Analyst Conference Call

    An Analyst Conference Call will be conducted today, Thursday, June 26,
2008 at 11:30 a.m. Eastern Time/8:30 a.m. Pacific Time. Analysts and
institutional investors are invited to dial in to the call at 1-706-634-5011
or toll free in North America at 1-866-234-7330. Media and all other
interested parties are asked to listen to the Web cast at
http://viavid.net/dce.aspx?sid=000052AC. The Web cast will be available for 90
days following the live transmission.

    Statements contained in this press release relating to future results,
events or developments, for example, statements containing the words
"believes," "may," "could", "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects", "goal" and similar expressions, are
"forward-looking statements" or "forward-looking information" under applicable
United States and Canadian securities laws. Forward-looking statements or
information may involve, but are not limited to, comments with respect to our 
 planned activities, business plan and strategies and their future
implementation, and our expectations for our financial condition and the
results of, or outlook for, our business operations generally. Forward-looking
statements or information are subject to the related assumptions made by us
and involve known and unknown risks, uncertainties and other factors that may
cause actual results, events or developments to be materially different from
those expressed or implied by such statements or information.
    Many of such risks, uncertainties and other factors form part of our
underlying assumptions, and include, among other things, financial risks that
would affect our operations such as our available working capital and cash
flows and whether and for how long available funds will be sufficient to fund
our operations and our ability to raise additional capital as and when needed;
our need for substantial additional funding to conduct research and
development and commercialization activities; our ability to establish, and
our dependence upon, relationships with strategic alliance partners to develop
and commercialize products; technological changes that impact our existing
products or our ability to develop and commercialize our products; our ability
to obtain and enforce timely patent and other intellectual property protection
for our technology and products; our ability to obtain and maintain rights to
technology from licensors; liability for patent, product liability and other
claims asserted against us; commercialization limitations imposed by patents
owned or controlled by third parties; technical risk in research and
development; adverse results or unexpected delays in product development and
clinical trials; our ability to retain, and our reliance upon, third party
suppliers, manufacturers and distributors; our ability to attract and retain
qualified personnel; our ability to effectively and efficiently manage the
planned growth of our operations; our ability to obtain, and the timing of,
necessary regulatory approvals; our ability to profitably sell our products at
prices that would be acceptable to third-party reimbursement programs;
competition including competition from others with significantly more
resources; market acceptance of our products and the size of our markets;
changes in business strategy or development plans; changes in, or the failure
to comply with, governmental regulations; fluctuations in interest rates and
foreign exchange rates; seasonality including government budget cycles;
general economic and business conditions where we operate; and other factors
referenced in our annual report, our Annual Information Form (AIF) (Form 40-F
in the U.S.) and other filings with Canadian and United States securities
regulatory authorities.
    Given these uncertainties, assumptions and risks, readers are cautioned
not to place undue reliance on such forward-looking statements or information.
We disclaim any obligation to update, or to publicly announce any revisions
to, any such statements or information to reflect future results, events or
developments.




For further information:

For further information: Response Biomedical Contacts: Bill Wickson,
Manager, Investor Relations, Response Biomedical Corporation, Tel (604)
456-6073, Email: bwickson@responsebio.com; Brian Korb, Vice President, The
Trout Group LLC, Tel: (646) 378-2923, Email: bkorb@troutgroup.com

Organization Profile

RESPONSE BIOMEDICAL CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890